Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica LSE:OXB London Ordinary Share GB0006648157 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.11p -1.29% 8.39p 8.36p 8.39p 8.72p 8.35p 8.50p 6,550,994 13:18:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 27.8 -20.3 -0.6 - 259.12

Oxford Biomedica (OXB) Latest News

More Oxford Biomedica News
Oxford Biomedica Takeover Rumours

Oxford Biomedica (OXB) Share Charts

1 Year Oxford Biomedica Chart

1 Year Oxford Biomedica Chart

1 Month Oxford Biomedica Chart

1 Month Oxford Biomedica Chart

Intraday Oxford Biomedica Chart

Intraday Oxford Biomedica Chart

Oxford Biomedica (OXB) Discussions and Chat

Oxford Biomedica (OXB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
12:32:248.3811,811990.02O
12:29:438.398,584720.20AT
12:27:258.3722,4801,881.22O
12:23:468.3811,9561,001.91O
12:20:188.381,721144.26O
View all Oxford Biomedica trades in real-time

Oxford Biomedica (OXB) Top Chat Posts

DateSubject
21/7/2017
09:20
Oxford Biomedica Daily Update: Oxford Biomedica is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker OXB. The last closing price for Oxford Biomedica was 8.50p.
Oxford Biomedica has a 4 week average price of 5.30p and a 12 week average price of 4.44p.
The 1 year high share price is 11.25p while the 1 year low share price is currently 3p.
There are currently 3,088,420,525 shares in issue and the average daily traded volume is 18,488,708 shares. The market capitalisation of Oxford Biomedica is £259,118,482.05.
13/7/2017
14:32
stocktastic: 'As for the IPO, a pet subject of yours, I can't think of a better example showing that when you raise something which is plainly tripe' Here is the basis for my speculation: - The OXB share price had risen phenomenally to 12p - Worldwide, there was a massive biotech IPO bubble going on, with the window wider than it has ever been - OXB was flagging how US listed comparators got much better valuations - OXB needed cash - OXB switched to Jeffries - a firm with great presence in the UK and EU as well as US - also one of the top firms for healthcare - Many of the directors all buying smallish sums around the same time at what were historically high price levels. No honest poster would call that 'tripe' So you just think it's a coincidence that most/all of the directors bought relatively small quantities of stock around the highs? You think OXB would be paying high rates of interest if they could have taken a rare opportunity to tap the US markets? Coincidence that OXB announced a fundraiser that included a private placing in the US, shortly after my IPO-failed speculation? My view on that was that they were making the most of parties that had become interested through a US listing attempt It's actually all quite plausible. Certainly no need to call it tripe
12/7/2017
21:58
harry s truman: And a tweet from Novartis thanking the trial families for their support. I think there's a 50 / 50 chance that the OXB share price will go up tomorrow.
11/7/2017
14:01
stocktastic: 'revisionist history' eh? Nothing revised there 'I must remember that escape for future reference - claim the other person raised it first' You're perhaps misinterpreting as I didn't do that at all.. Re IPO theory - I just reiterated it is MY opinion, but asked whether OXB could confirm it to be wrong when I speculate they tried to list in the US Then I said that I disagree with your view that they'd not be able to afford a US listing - since as explained, half the purpose of listing would be to raise cash. So where's the 'escape' and claiming someone else raised it first??? Look at my US listing theory this way - The OXB share price had risen phenomenally to 12p - Worldwide, there was a massive biotech IPO bubble going on, with the window wider than it has ever been - OXB was flagging how US listed comparators got much better valuations - OXB needed cash - OXB switched to Jeffries - a firm with great presence in the UK and EU as well as US - also one of the top firms for healthcare - Many of the directors all buying smallish sums around the same time at what were historically high price levels. So you're suggesting that the company took on loans at a high rate of interest rather than try and capitalise on a rare opportunity to list in the US on great terms? It actually seems rather unlikely to me that OXB didn't try to list in the US IMO the reason the company failed was the early stage of products, the past failures and the lower appetite for manufacturing/royalies vs more traditional biotech listings etc.
06/7/2017
14:28
asat91: As I understand it, OXB are spending £40mill per year at the moment, and their revenue is about 20-30mill without CTL019. So if they make the £65mill/year estimated from CTL019, and maintain their current revenue and costs this would give a pre-tax profit of about £40mill/year. Earnings per share in that situation would be 40mill/3billion = 0.013. P/E ratio at current share price would be 7.5, which as marcus says would be very low for a promising biotech company in oncology gene therapy, especially a biotech company that is so valuable to a giant like Novartis. Expect a P/E ratio of between 15 and 25 by December 2017 or by December 2018 when they release their profits (assuming approval and sales of CTL019) which would give a share price of 25p+. Better investment than any bank account that's for sure! Even if we will have to wait until Dec 18 for the profit statement after CTL019 has been selling a while. And of course with good news coverage, positive broker reports and popularity comes market hysteria which could even push the share price up to something ridiculous like 40p or 50p at some point next year. I wasn't around for Trovax but I assume that's what happened there? If Novartis do decide to buy/acquire OXB at some point over the next year or two, we could be looking at a sale price of close to £1billion which Novartis can easily afford with cash reserves of £14billion+, and would be more than 3x current OXB share price. What do you guys think?
02/7/2017
18:54
gareth jones: I fear for the OXB share price in the morning given all this good news! Seriously we should see good volume and hopefully a positive share price leading up to the FDA meeting on 12th. If we dont get an announcement/decision on 12th we may see a draw back as short termers have to bail out but it should make little difference to all LTH's. MM's will earn their money in the next couple of weeks as they respond to market sentiment and demand in setting buy/sell prices.
22/6/2017
15:43
rrr: While I agree the main point is about patients, as you ask I think it will get approval and that that will be good for OXB share price (but to what extent I leave to others). rrr
22/6/2017
12:05
rrr: marcus thank you! I am just so excited by this, it is so utterly amazing. I'm not talking about the OXB share price, I'm talking about the medicine and the patients, who could easily be any of us. These are sounding suspiciously like cures - for the previously incurable. utterly amazing and wonderful
31/3/2017
19:04
sddavies1: Its a frustrating shame that, despite Novartis delivering on their promises for something that is key to our future, the OXB share price is still languishing below its recent highs.Instead of remaining silent. Its high time BoD started to make noises about how they plan to deal with the debt that has cast a shadow over proceedings.I know that everything is starting to look rosy on paper but to me it seems that unless they start to add capital value soon, we will be sittings ducks for a nice cheap buy out.
30/1/2017
19:38
beanol: Yes Marcus indeed. Very promising. BUT why with all this positive news and it being fairly clearly known that Oxb has a role to play which will hugely benefit the company has there been no upwards movement in the Oxb share price - aren't markets supposed to rise ahead of major announcements? Or is the market so mistrustful of Oxb management and its past record that.....
22/1/2017
01:10
beanol: HarryFrom reading your always thoughtful and considered posts for years I know you have a deep well of understanding about Oxb which the rest of us profit from and I certainly for one will never rival or come near. But right now (2017) there's a business imperative on the march - Novartis and Car T therapy : I am clear from a combination of the following: letter LT wrote following two specific complaints I made, speaking to people connected to Novartis, others involved in the haplessly managed fund raising last year that this year if not now or never for Oxb will certainly be pretty critical for the company. No substantive progress for Novartis no progression for Oxb share price. But if progress for Novartis and Car T then we get into a virtuous circle which will per force mean a closer relationship or more with Novartis. Given what the latter have riding on Car T there is likely to be no other alternative. I can't believe Trovax or any other drug from Oxb's stable will (really) come into the reckoning. Time will tell obviously but let's see where we are end of April. In writing this I realise I am becoming a one trick pony but in spite of its pretensions to wider success so I'm afraid Oxb may be becoming too.
Oxford Biomedica share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20170721 12:52:18